ReviewBiomarker research2026
The dual balance of the cytokine network: key messengers of immune activation and triggers of cytokine storm.
Review in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cytokine network is the central regulatory system for intercellular communication within the immune system. Its proper function depends on the dynamic balance between pro-inflammatory and anti-inflammatory cytokines. Through complex positive and negative feedback loops, this balance precisely regulates the intensity and duration of immune responses, thereby playing a critical role in both physiological and pathological states. This review systematically summarizes the compositional features and classification framework of the cytokine network, as well as the mechanisms by which it maintains homeostasis under physiological conditions. It further examines the manifestations of cytokine network imbalance in diseases such as sepsis, psoriasis, rheumatoid arthritis, inflammatory bowel disease, and cancer. Available evidence suggests that these imbalances drive disease onset and progression primarily through cascade amplification of pro-inflammatory signaling, insufficient generation of anti-inflammatory signals, and aberrant epigenetic modification. These pathological changes are strongly influenced by factors such as infection, autoimmune dysregulation, and the tumor microenvironment (TME), together constituting the core pathological axis of "cytokine imbalance-immune dysregulation-disease progression." This review also summarizes current clinical strategies targeting the cytokine network, including monoclonal antibodies, Janus kinase (JAK) inhibitors, and emerging modalities such as bispecific antibodies and chimeric antigen receptor (CAR) cell therapy. In addition, it evaluates the clinical efficacy, potential risks, and future directions of these approaches. In summary, a deeper understanding of the binary balance within the cytokine network not only broadens our knowledge of immune regulation but also provides a theoretical basis and translational framework for the development of precision immune-targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.